¹⁸F-NaF PET/CT and ¹¹C-Choline PET/CT for the initial detection of metastatic disease in prostate cancer: overview and potential utilization.
With the rapid increase in new therapies to treat advanced prostate cancer, improved diagnosis tools are necessary to help refine patient management throughout the entire disease course. Many radiopharmaceuticals, most of which are imaged using positron emission tomography/computed tomography (PET/CT), are in development; two of these newer radiopharmaceuticals are ¹⁸F-sodium fluoride (NaF) and radiolabeled choline. Compared with traditional imaging, use ¹⁸F-NaF has been shown to improve sensitivity and specificity, and radiolabeled choline has been shown to detect recurrent and metastatic disease earlier. We briefly review these two imaging technologies and provide potential utilization strategies based on available data.
Phillip J
PJ
Koo
E
E
David Crawford
D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D002250:Carbon Radioisotopes; D002794:Choline; D005462:Fluorine Radioisotopes; D006801:Humans; D008297:Male; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000706:statistics & numerical data*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D019275:Radiopharmaceuticals; D012969:Sodium Fluoride; D014057:Tomography, X-Ray Computed / Q000706:statistics & numerical data*
D002250:Carbon Radioisotopes; D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D012969:Sodium Fluoride; D002794:Choline